A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
J Enzyme Inhib Med Chem
; 35(1): 391-397, 2020 Dec.
Article
in En
| MEDLINE
| ID: mdl-31865754
ABSTRACT
The emergence of tumour recurrence and resistance limits the survival rate for most tumour-bearing patients. Only, combination therapies targeting pathways involved in the induction and in the maintenance of cancer growth and progression might potentially result in an enhanced therapeutic efficacy. Herein, we provided a prospective combination treatment that includes suberoylanilide hydroxamic acid (SAHA), a well-known inhibitor of histone deacetylases (HDACs), and SLC-0111, a novel inhibitor of carbonic anhydrase (CA) IX. We proved that HDAC inhibition with SAHA in combination with SLC-0111 affects cell viability and colony forming capability to greater extent than either treatment alone of breast, colorectal and melanoma cancer cells. At the molecular level, this therapeutic regimen resulted in a synergistically increase of histone H4 and p53 acetylation in all tested cell lines. Overall, our findings showed that SAHA and SLC-0111 can be regarded as very attractive combination providing a potential therapeutic strategy against different cancer models.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Phenylurea Compounds
/
Sulfonamides
/
Carbonic Anhydrase Inhibitors
/
Histone Deacetylase Inhibitors
/
Carbonic Anhydrase IX
/
Histone Deacetylases
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
J Enzyme Inhib Med Chem
Journal subject:
BIOQUIMICA
/
QUIMICA
Year:
2020
Type:
Article
Affiliation country:
Italy